Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai and Minophagen Pharmaceutical have signed a licensing agreement for the development and commercialization of bexarotene, a cutaneous T-Cell lymphoma treatment, in Asia, Oceania, the Middle East and Eastern Europe.
Subscribe to our email newsletter
As per the agreement, Minophagen will have the exclusive rights to develop and commercialize the drug candidate.
Eisai holds the right of first negotiation for the commercialization of the agent in the licensed territories, if it is approved.
Eisai is eligible to receive a one-time payment upon conclusion of the agreement, milestone payments and royalties on future sales, from Minophagen.
FDA had granted orphan drug status to bexarotene in 1999, and is presently approved and marketed as a treatment for recurrent and refractory CTCL in over 20 countries.